Draft Guidance
FDA draft GFI #256B separates discretion from CGMP duties
FDA labels Draft CVM GFI #256B as not for implementation and says it contains nonbinding recommendations for comment. The draft describes a future enforcement policy for certain animal drugs compounded from bulk substances in federally registered facilities, while stating that FDA generally would not intend to exercise enforcement discretion for current good manufacturing practice violations at those facilities.